|Day Low/High||3.22 / 3.38|
|52 Wk Low/High||0.29 / 5.77|
The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
Dealmaking is going strong and looks set to continue as mental health becomes a key investment theme going forward.
As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category.
Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.
Investors are anxious to grab the next penny stock that may be poised to jump on the mind-blowing bubble. Here they are.
Mydecine Innovations Group -- formerly known as NewLeaf -- signed an agreement with the University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences.
As crisis turns into one of mental health as well as physical health, some firms are experimenting with use of LSD and 'magic mushroom' compounds.